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Abstract
Background: Asthma and wheezing disorders in childhood and adulthood are clinically heterogeneous regarding
disease presentation, natural course, and response to treatment. Deciphering common disease mechanisms in
distinct subgroups requires harmonized molecular (endo-) phenotyping of both children and adult patients with
asthma in a prospective, longitudinal setting.
Methods: The ALL Age Asthma Cohort (ALLIANCE) of the German Center for Lung Research (DZL) is a prospective,
multi-center, observational cohort study with seven recruiting sites across Germany. Data are derived from four sources: (a)
patient history from medical records, (b) standardized questionnaires and structured interviews, (c) telephone interviews,
and (d) objective measurements. Objective measurements include amongst others lung function and quantitative
assessment of airway inflammation and exhaled breath, peripheral blood, skin, nasal, pharyngeal, and nasopharyngeal
swabs, nasal secretions, primary nasal epithelial cells, and induced sputum. In cases, objective measurements and
biomaterial collection are performed regularly, while control subjects are only examined once at baseline.
Discussion: The standardized and detailed collection of epidemiological and physiological data, and the molecular deep
phenotyping of a comprehensive range of biomaterials in a considerable number of study participants across all ages are
the outstanding characteristics of this multi-center cohort. Despite extensive biomaterial sampling, and a recruitment
strategy that also includes pre-school children as young as 6 months, attrition is low. In children 83.9%, and in adults
90.5% attended the 12-month follow-up. The earliest time-point to include cases, however, is disease manifestation.
Therefore, unraveling mechanisms that drive disease onset is limited, as this question can only be answered in a
population-based birth cohort. Nonetheless, ALLIANCE offers a unique, integrative and inter-disciplinary framework with a
comprehensive molecular approach in a prospective and identical fashion across ages in order to identify biomarkers and
predictors for distinct childhood wheeze and asthma trajectories as well as their further course during adulthood.
Ultimately, this approach aims to translate its most significant findings into clinical practice, and to improve asthma
transition from adolescence to adulthood.
Trial registration: NCT02496468 for pediatric arm, NCT02419274 for adult arm.
Keywords: Wheeze, Asthma, Pediatric pulmonology, Phenotype, Endotype, Biomarker
* Correspondence: t.bahmer@lungenclinic.de
Oliver Fuchs and Thomas Bahmer are shared first authors.
Klaus F. Rabe, Matthias V. Kopp, Gesine Hansen and Erika von Mutius are
shared last authors.
4LungenClinic Grosshansdorf GmbH, Grosshansdorf, Germany
11Airway Research Center North (ARCN), German Center for Lung Research
(DZL), Grosshansdorf, Germany
Full list of author information is available at the end of the article
© The Author(s). 2018, corrected publication November 2018. Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits
unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s)
and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons
Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in
this article, unless otherwise stated.
Fuchs et al. BMC Pulmonary Medicine          (2018) 18:140 
https://doi.org/10.1186/s12890-018-0705-6
Background
Wheezing disorders and asthma are the most prevalent
chronic respiratory diseases both in childhood and adult-
hood. About 25–30% of children have at least one epi-
sode of wheeze before their 3rd birthday, but
considerable clinical heterogeneity exists [1, 2]. Many of
these children become symptom-free between 3 and
8 years of age, but some go on to persistent asthma in
later childhood and adulthood [3].
Although the characteristic clinical manifestations of
asthma in children and in adults are rather uniform with
wheezing, shortness of breath and cough, population-based
clinical and genetic studies suggest that asthma is not one
disease but many [4]. Despite its prevalence, little is known
about the diverse underlying pathomechanisms determin-
ing the different asthma phenotypes both in children and
adults, including asthma transition (Fig. 1) [3–6]. Affected
individuals vary with regard to severity and nature of their
primary complaints, but also in relation to comorbidities,
response to treatment, and to the course of the disease
throughout life [2]. The different asthma phenotypes and
trajectories are presumably caused by diverse underlying
pathophysiological processes. Recent related research also
takes complex, explicit molecular data into account to bet-
ter link biology to clinical presentation which may then be
called an asthma endotype [5, 7].
So far, most (endo)-phenotyping has been applied in
children and adults separately. Consequently, there is a
substantial intrinsic bias towards more pathophysiological
data from cross-sectional studies in adults and more epi-
demiological data for children, respectively [3]. However,
common predictors and subsequent targeted treatment -
or even prevention strategies - are urgently needed, espe-
cially early in life. Asthma research to date should there-
fore integrate standardized molecular approaches in
identical ways in longitudinal studies in paediatric and
adult populations [3, 8, 9]. The decoding of mechanisms
underlying the asthma syndrome, and their translation to
the individual patient across all ages is the overall aim of
the All Age Asthma Cohort (ALLIANCE) of the German
Centre for Lung Research (Deutsches Zentrum für Lun-
genforschung, DZL).
Methods/design
Where is the study located and how is it funded?
The ALLIANCE infrastructure is provided by the partici-
pating sites of the German Centre for Lung Research
(DZL) and associated study centres, i.e. university hospitals,
academic and private research institutions in Luebeck,
Grosshansdorf, Borstel, Hannover, Munich, Marburg and
Cologne. Direct costs of the ALLIANCE Cohort are being
paid by project grants (first funding period 2011–2015 and
second funding period 2016–2020) from the German Fed-
eral Ministry of Education and Research (Bundesminister-
ium für Bildung und Forschung, BMBF) as part of the DZL
funding. All studies were approved by the local ethics com-
mittees and are registered at clinicaltrials.gov (paediatric
arm: NCT02496468; adult arm: NCT02419274).
Fig. 1 Wheeze and asthma phenotypes during childhood and adulthood. About 25–30% of children have at least one episode of wheeze before
their 3rd birthday, but considerable clinical heterogeneity exists (broken line box I). Children with transient wheeze become symptom-free before
school-age, those with non-atopic asthma after about 8 years of age. However, some, especially those with persistent atopic wheeze and
seasonal triggers of wheeze go on to persistent asthma in later childhood and adulthood. Interestingly, girls present with new-onset asthma in
significant numbers during adolescence, thereby adding to turning the sex-based bias from male towards female sex. While there is also new-
onset-asthma during adulthood, it is unclear whether differences between persistent childhood asthma phenotypes continue throughout
transition (broken line box II) into adulthood
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Who is in the cohort?
Study participants for both arms (paediatric and adult) of
ALLIANCE are recruited at the participating study sites
(for details see Fig. 2). In the case of children with
new-onset disease, cases were additionally recruited in pri-
vate practices of registered paediatricians. For these chil-
dren, disease course can be followed from the beginning
on, and they are rarely seen in a clinical but much more
often in a primary care setting due to their early disease
state. Healthy paediatric controls (age- and sex-matched)
were recruited in the same centres, via notices across
campus and in private practices of registered paediatri-
cians, as well as during clinics of separate subspecialties
(e.g. paediatric growth) or if scheduled for short surgical
interventions.
Adult patients with asthma are recruited from the in-
patient and outpatient departments of LungenClinic
Grosshansdorf and of the Medical Clinical of Research
Center Borstel, and from an institutional database that is
used for clinical trials (Pulmonary Research Institute at
LungenClinic Grosshansdorf ). Healthy adult controls
were also recruited from an existing institutional data-
base and by advertisement.
General in−/exclusion criteria for children, definition of
childhood cases and controls
For children, the following inclusion criteria apply in
addition to informed consent of either parent or care-
taker and of the child if aged 8 years or older: age
6 months to 18 years, term delivery (≥ 37 weeks); active/
passive understanding of German. Steroid−/leukotriene
receptor antagonist (LTRA)-naivety is defined as no use
of inhaled or systemic corticosteroids or LTRA for at
least four months prior to inclusion. Exclusion criteria
for participants of the paediatric arm of ALLIANCE are:
known inborn or perinatal pulmonary disease; pulmon-
ary malformation; oxygen therapy after birth with a dur-
ation of more than 24 h; ventilator support or
mechanical ventilation after birth; diagnosis of cystic fi-
brosis; primary ciliary dyskinesia; heart failure diagnosed
after birth affecting pulmonary circulation; major re-
spiratory diseases such as e.g. interstitial lung disease;
and any current non-atopic comorbidities. Moreover,
children are excluded from study visits and biomaterial
collection in the case of fever of at least 38.5 °C during
the last two weeks prior to the planned visit.
Childhood cases are specified as either having
doctor-diagnosed wheeze during at least 2 occasions dur-
ing the last 12 months (age < 6 years) or as having
doctor-diagnosed asthma (age ≥ 6 years) with diagnosis ac-
cording to current guidelines including lung function [10,
11]. Healthy controls are defined as children without
wheeze or asthma and otherwise applying the same in-
and exclusion criteria as mentioned above. Adolescent
cases turning 18 years of age will automatically enter tran-
sition into the adult arm of ALLIANCE, with identical
data and biomaterial collection as prior to transition.
General in−/exclusion criteria for adults, definition of
adult cases and controls
The following inclusion criteria apply in addition to in-
formed consent for participants who are newly recruited
Fig. 2 Consolidated Standards of Reporting Trials (Consort) Diagram displaying details for recruitment of participants of the DZL All Age Asthma
Cohort (ALLIANCE). See text for details.
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during adulthood: age ≥ 18 years, active/passive under-
standing of German, and an established diagnosis of
asthma according to current guidelines [10, 11]. Partici-
pants are allowed to be current or former smokers to
avoid significant selection bias. Patients with asthma and
a relevant smoking history are accurately screened for
features distinguishing asthma from chronic obstructive
pulmonary disease (COPD): age at onset, pattern and
time course of symptoms, personal and family history,
variable or persistent airflow limitation, lung function in
symptom-free episodes, and severe hyperinflation [12]. If
no clear distinction is possible and patients currently
present with predominant features of COPD, i.e. relevant
gas exchange impairment or hyperinflation, or signs/
symptoms of chronic bronchitis or emphysema (if com-
puter tomography scan available) [13], they are excluded
from the study. Further exclusion criteria are: severe
upper respiratory tract infection (URTI), or severe ex-
acerbation during the last 4 weeks, ensuring that pa-
tients are in a stable phase of their disease [10, 11].
Controls had to be without any pulmonary disease but were
allowed to have concurrent allergic rhinoconjunctivitis.
Fig. 3 a,b: The DZL All Age Asthma Cohort (ALLIANCE): time-flow of recorded data (a), as well as of tests and procedures (b). See text for details.
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Table 1 Detailed description of collected data and measurements in the DZL All Age Asthma Cohort (ALLIANCE)
Data Collection (Hospital Records,
Questionnaires, and Telephone
Interviews)
Paediatric Arm Adult Arm
Extraction of Routine data Source: Questionnaires (Baseline and Follow-Up)
• study participant: name, gender, city and country of
birth, date of birth, birth mode, gestational age,
birth weight, birth length, multiple birth, birth
order, vaccinations, onset of puberty, physical
activity, type of child care, desensitization, measures
to reduce allergen exposure, asthma training
• demographic and sociodemographic information:
mother and father: names, country of birth, contact
data (home address, telephone number, email
address), country of birth (up to grand-parents),
birth year, graduation, professional training, number
of children and other persons in same household
• feeding (breast-fed, hypoallergenic supplement)
• family history (asthma, allergic rhinoconjunctivitis,
atopic dermatitis, therapy, comorbidities assessed
for parents and grand-parents as well as siblings)
• families’ paediatrician name and address as well as
of general practitioner
Source: Identification Questionnaire, Screening
Questionnaire, Baseline Questionnaire (patient
version), Baseline Questionnaire (physician version)
• study participant: name, gender, city and country of
birth, date of birth, birth mode, multiple birth,
desensitization, measures to reduce allergen
exposure, asthma training
• demographic and sociodemographic information:
contact data (home address, telephone number,
email address), graduation, professional training,
number of persons in same household (current and
as child), country of birth of mother and father
• feeding (breast-fed)
• family history (asthma, assessed for parents and
grand-parents as well as siblings)
• patient’s pulmonologists name and address
• vaccinations
• atopy status according to study physician (allergic
comorbidities, allergic sensitization without
symptoms, no allergies), smoking status (current
and former, cumulative pack years), alcohol
consumption
• comorbidities that might mask severe asthma;
cardiovascular and neurologic comorbidities
Respiratory Symptoms Source: Questionnaires (Baseline and Follow-Up)
• Wheeze and cough ever prior to visit (age of onset,
number, duration, severity, triggers, seasonal
pattern of symptoms, treatment/medication)
• Wheeze and cough during last 12 months prior to
visit (number, duration, severity, triggers, seasonal
pattern of symptoms, treatment/medication incl.
Rout and technique as well as adherence, asthma
control, assessed according to GINA [10] guidelines
and by ACT [15, 37]
• Wheeze and cough in relation to exacerbation
(number, duration, severity, triggers of symptoms,
treatment/medication)
• Asthma Control assessed according to GINA [10], C-
ACT, ACT [15, 37]
• Allergic and non-allergic comorbidities (allergic
rhinitis, atopic dermatitis, food allergy, age of onset,
severity, triggers, seasonal pattern of symptoms,
treatment/medication)
• Medication (ever as well as resolution down to one
month during last 12 months prior to routine study
visit, resolution down to one day during last 4–
5 weeks prior to exacerbation visits)
Source: Baseline and FollowUp Questionnaire
(patient version), Baseline and FollowUp
Questionnaire (physician version) ACT, ACQ, AQLQ,
MFI-20
• first symptoms (age), first diagnosis and disease
duration
• Asthma Control assessed according to GINA [10],
ACT [15], ACQ [16]
• Health related quality of life assessed by AQLQ [17]
• Fatigue assessed by MFI-20 [18]
• Frequency of severe exacerbations, hospital
admissions. Mechanical ventilation and asthma-
related rehabilitation (ever and previous 12 months)
• Allergic and non-allergic comorbidities (allergic
rhinitis, atopic dermatitis, food allergy, age of onset,
severity, triggers, seasonal pattern of symptoms,
treatment/medication)
• Current asthma medication (including current
dosage of inhaled and oral corticosteroids),
important co-medication (ß-blockers, Aspirin),
former medication (including immune modulators),
desensitization (former or current), work related
symptoms
Environmental Exposures Source: Questionnaires (Baseline and Follow-Up)
• maternal warning signs sub partu (infection, fever,
antibiotics or other medication, chorioamnionitis),
signs of postpartal infection of child
• maternal or paternal smoking during pregnancy
and later, further active smoking in household
• traffic exposure at home (major street)
• mold exposure at home (assessment,
refurbishment)
• pet exposure at home (type of pet)
Source: Baseline Questionnaire (patient version),
Follow-Up Questionnaire (patient version)
• maternal or paternal smoking during pregnancy
and later, further active smoking in household
• mold exposure at home (assessment,
refurbishment)
• pet exposure in childhood (dogs)
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Table 1 Detailed description of collected data and measurements in the DZL All Age Asthma Cohort (ALLIANCE) (Continued)
Objective Measurements Paediatric Arm Adult Arm
Measurements of lung function and
inflammation of airways, body
composition and physical activity,
imaging
1. Anthropometric data and vital parameters at study
date:
• Body weight and length, body temperature, heart
beats per minute, respiratory rate, oxygen
saturation
2. Exhaled breath measurement by electronic nose
(e-nose) [21]:
• Cyranose 320, Sensigent, Arrow Highway, USA
• Main outcome parameters: patterns of volatile
organic compounds (VOCs)
3. Exhaled breath measurement by gas
chromatography-mass spectrometry (GC-MS) [22]:
• Sampling device provided by Fraunhofer ITEM,
Hannover
• Main outcome parameters: patterns of volatile
organic compounds (VOCs) by GC-MS
4. Single- and multiple breath washouts (nitrogen
washout with 100% oxygen, O2) [19, 30]:
• Ultrasonic flowmeter (EcoMedics AG, Duernten,
Switzerland); single- and multiple-breath measure-
ment, mouth-piece, filter, nasal clamp
• Main outcome parameters (multiple breath): lung
volume (functional residual capacity, FRC),
ventilation inhomogeneity (lung clearance index,
LCI)
• Main outcome parameters (single breath): phase III
and IV analysis (SIII/ phase III slope, closing volume)
5. Measurement of exhaled nitric oxide (eNO) [20]:
• Rapid-response chemoluminescence analyzer (CLD
88, EcoMedics AG, Duernten, Switzerland); single-
breath manoeuvre, filter, no nasal clamp
• Main outcome parameter: mean eNO, NO
production (eNO x expiratory flow)
6. Spirometry and bodyplethysmography [28, 29]:
• Jaeger MasterScreen Body, BD Carefusion, Germany;
mouthpiece, filter, nasal clamp
• Main outcome parameters: lung volumes
(intrathoracic gas volume/functional residual
capacity, FRC, total lung capacity, TLC, residual
volume, RV), airway resistance, forced expiratory
flows and volumes, each before and after
bronchodilator
7. Planned: thoracic magnetic resonance imaging
(tMRI)
1. Anthropometric data, vital parameters and body
composition at study date:
• Body weight and length, waist circumference, body
temperature, heart beats per minute, respiratory
rate, blood pressure, oxygen saturation,
bioimpedance measurement (Nutri Plus, Data-Input
GmbH, Darmstadt, Germany)
• Main outcome parameters (bioimpedance):
Resistance (50 kHz), Reactance (50 kHz), extra
cellular mass/ body cell mass index (ECM/BCM
Index)
2. Exhaled breath measurement by gas
chromatography-mass spectrometry (GC-MS) [22]:
• Sampling device provided by Fraunhofer ITEM,
Hannover
• Main outcome parameters: patterns of volatile
organic compounds (VOCs) by gas
chromatography-mass spectrometry (GC-MS)
3. Single and multiple breath washouts (nitrogen
washout with 100% oxygen, O2) [19, 30]:
• VMax ENCORE (Viasys Healthcare), Carefusion
Germany; mouthpiece, filter, nasal clamp
• Main outcome parameters (multiple breath): lung
volume (functional residual capacity, FRC),
ventilation inhomogeneity (lung clearance index,
LCI)
• Main outcome parameters (single breath): phase III
and IV analysis (SIII/ phase III slope, closing volume)
4. Measurement of exhaled nitric oxide (eNO) [20]:
• Hand-held device (NIOX MINO, Circassia AB, Upp-
sala, Sweden); single breath manoeuvre, filter, no
nasal clamp
• Main outcome parameter: mean eNO
5. Bodyplethysmography [33]:
• Jaeger MasterScreen Body, BD Carefusion, Germany;
mouthpiece, filter, nasal clamp
• Main outcome parameters: lung volumes
(intrathoracic gas volume/functional residual
capacity, FRC, total lung capacity, TLC, residual
volume, RV), airway resistance, closing volume,
closing capacity
6. Impulse Oscillometry (IOS) [23]:
• Masterscreen IOS, BD Carefusion, Germany;
mouthpiece, filter, nasal clamp
• Main outcome parameters: Resistance (5 Hz, 20 Hz,
Frequency dependent resistance FDR), Reactance
(5 Hz, AX, Fres)
7. Capnovolumetry [24]:
• Masterscreen Capno, Carefusion Germany;
mouthpiece, filter, nasal clamp
• Main outcome parameters (multiple breath):
capnogram phase II and III analysis (Vm2550, SR23),
dead space volumes
• Main outcome parameters (single breath):
capnogram phase II, III and IV analysis (Vm2550,
SR23, SIII/ phase III slope, closing volume), dead
space volumes
8. Single Breath diffusing capacity (DLCO) [31]:
• VMax ENCORE (Viasys Healthcare) and Jaeger
MasterScreen Body, BD Carefusion Germany;
mouthpiece, filter, nasal clamp
• Main outcome parameters: transfer factor of the
lung for carbon monoxide (TLCO) and related to
alveolar volume (TLCO/VA)
9. Spirometry [29]:
• VMax ENCORE (Viasys Healthcare) and Jaeger
MasterScreen Body, BD Carefusion Germany;
mouthpiece, filter, nasal clamp
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Table 1 Detailed description of collected data and measurements in the DZL All Age Asthma Cohort (ALLIANCE) (Continued)
• Main outcome parameters: forced expiratory flows
and volumes, each before and after bronchodilator
10. Bronchial provocation (Methacholine) [38]:
• VMax ENCORE (Viasys Healthcare), Jaeger
MasterScreen Body and MasterScreen IOS, BD
Carefusion Germany; mouthpiece, filter, nasal clamp
• Main outcome parameter: PC20 FEV1, PC40 R5Hz,
PC40 FRES
11. Daily Physical Activity (accelerometer based) [25,
26]:
• SenseWear Armband, BodyMedia Inc. Pittsburgh
(PA), USA
• Main outcome parameters: steps per day (SPD) and
indicators of daily energy expenditure
Sensitization Specimen: peripheral blood
1. Measurement of total IgE, eosinophils in white
blood cell count
2. Specific IgE (sIgE) measurement by chip
technology (Immunocap ISAC 121) [39]:
• Immunocap ISAC, Phadia, Uppsala, Sweden
• Single components
• Main outcome parameter: sensitization pattern to
components
3. sIgE measurement by Sandwich-ELISA, Immunocap
[40]:
• Immunocap, Phadia, Uppsala, Sweden
• Allergen extracts
• Main outcome parameter: sensitization pattern to
extracts
4. sIgE measurement by Immunoblot:
• Euroimmun AG, Luebeck Germany
• Allergen extracts
• Main outcome parameter: sensitization pattern to
extracts
Specimen: peripheral blood, skin
1. Measurement of total IgE, eosinophils in white
blood cell count
2. Specific IgE (sIgE) measurement by chip
technology (Immunocap ISAC 121) [39]:
• Immunocap ISAC, Phadia, Uppsala, Sweden
• Single components
• Main outcome parameter: sensitization pattern to
components
3. sIgE measurement by Immunoblot:
• Euroimmun AG, Luebeck Germany
• Allergen extracts
• Main outcome parameter: sensitization pattern to
extracts
4. Skin Prick Test
• Allergopharma, Hamburg, Germany
• Allergen Extracts
• Main outcome parameter: sensitization pattern to
extracts
Microbiome Specimen: skin swabs, nasal swabs, (naso-)pharyngeal
swabs, stool samples, induced sputum
• Analysis by ultra-high-throughput sequencing
• Analysis of microbiota in pharyngeal swab, stool
and sputum samples
Specimen: pharyngeal swabs, induced sputum
• Analysis by ultra-high-throughput sequencing
• Analysis of microbiota in pharyngeal swab and
sputum samples
Viruses, Virome Specimen: nasopharyngeal swabs
• Targeted analysis by virus-specific PCR
• Virome by whole-genome sequencing
Specimen: nasopharyngeal swabs
• Targeted analysis by virus-specific PCR
• Virome by whole-genome sequencing
Immunology Specimen: peripheral blood
• White blood cell count, high-sensitive CRP,
leukocyte subtypes by chip-cytometry [41]








• White blood cell count, high sensitive CRP,







Genomics Specimen: peripheral blood
• DNA extraction from whole blood
• Analysis of single nucleotide polymorphisms (SNPs)
Specimen: peripheral blood
• DNA extraction from whole blood
• Analysis of single nucleotide polymorphisms (SNPs)
Epigenomics Specimen: peripheral blood (also parents of cases)
• DNA extraction from whole blood, cell-specific (blood
cell sub-populations) and tissue-specific analyses
• Analysis of DNA methylation and histone
modification
Specimen: peripheral blood
• DNA extraction from whole blood
• Analysis of DNA methylation and histone
modification
Transcriptomics Specimen: peripheral blood, primary nasal epithelial
cells
• RNA extraction from whole blood or primary cells,
cell-specific (blood cell sub-populations) and tissue-
specific analyses
Specimen: peripheral blood, primary nasal epithelial
cells
• RNA extraction from whole blood or primary cells
• Analysis of RNA by array analysis and of candidates
by real-time PCR (RT-PCR)
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Details on study design, recruitment, and follow-up
The overall study design of the DZL Asthma Cohort
is shown in Fig. 3 a and b, and detailed later in the
text. Healthy controls are seen at the study centres
once, yet their age distribution will allow comparisons
across the whole age range of recruited cases. For
cases, the design includes a first study visit at time of
recruitment and regular yearly follow-up study visits
afterwards.
Before recruitment, in- and exclusion criteria for eli-
gible individuals are assessed by participating centres. In
the case of children, this is additionally performed with
screening leaflets used by participating primary care
physicians with parents being asked for consent to trans-
fer contact data to study centres prior to any communi-
cation between study centres and interested families.
After information about the study and informed consent
by study participants (> 8 years of age) and, if necessary,
all care-takers, the study phase starts with recruit-
ment and the first study visit of cases in each study
centre. On this occasion, lung function measurements
are performed, and questionnaires are used to assess
important clinical and epidemiological data. Further-
more, extensive biomaterial collections are imple-
mented (see Fig. 3 a and b for an overview over the
time flow of recorded data as well as tests and
procedures).
Recruitment of new cases for the paediatric arm of
ALLIANCE is on-going. From September 2013 until
and including December 2016, a total of N = 540 chil-
dren (n = 415 cases, thereof n = 209 preschool wheezers
and n = 206 childhood asthmatics, n = 125 healthy con-
trols) were recruited as eligible study participants. For
the adult arm, N = 255 study participants (n = 208 cases,
n = 47 healthy controls) were included until and includ-
ing December 2016 (see Fig. 2).
How often have they been followed up?
After 12 months, all cases are invited for the first
follow-up study visits at the study centres with identical
measurements and data collection as during the baseline
visit. On this occasion, a follow-up questionnaire is used
to reassess important clinical and epidemiological items,
likewise for all consecutive follow-up visits. In children,
equivalent follow-up visits are performed every 12 months,
while in adults, the schedule for deep-phenotyping
follow-up visits is stretched.
Data collected during follow-up of cases has been
added to the central database, quality controlled, and
is reported here. In contrast to children, primary re-
cruitment of adults was stopped in 2017 and only
continued for those individuals who are already par-
ticipants of the paediatric arm and turn adult during
the time-course of the study.
Until the end of 2016, there was reasonable attrition
during follow-up of cases (children and adults) as part of
ALLIANCE (see Table 2). Among eligible children, i.e. in-
dividuals recruited until and including 2015 and with pos-
sible follow-up until and including 2016, we lost n = 52 of
n = 324 children (16.0%) that should have completed study
visits 12 months after initial recruitment, while this was
the case for n = 17 of n = 172 (9.0%) 24 months, and for n
= 4 of n = 20 (20.0%) 36 months after initial recruitment,
respectively. Among eligible adults, n = 16 out of n = 169
(9.5%), who should have completed study visits 12 months
and n = 3 out of n = 81 (3.7%), who should have completed
study visits 24 months after initial recruitment, were lost
over time. All individuals lost to follow-up were due to
personal reasons. Further attrition during follow-up in
2017 and upcoming years will be evaluated regularly.
Demographics of the N = 795 study participants of the
DZL ALLIANCE cohort as part of the ALLIANCE data-
base (at baseline for cases, only including eligible study
participants) are displayed in Table 3 for both children
and adults.
What has been measured?
Data are derived from four sources: (a) hospital and med-
ical records (used to extract information about wheeze
and asthma diagnoses as well as in- and exclusion cri-
teria), (b) questionnaires and structured interviews, (c)
telephone interviews, and (d) objective measurements. A
Table 1 Detailed description of collected data and measurements in the DZL All Age Asthma Cohort (ALLIANCE) (Continued)
• Analysis of RNA by array analysis and of candidates
by real-time PCR (RT-PCR)
Metabolomics Specimen: peripheral blood, urine
• Targeted and non-targeted metabolomics from
serum and urine samples
• Analysis of several hundred human metabolites by
HPLC-MS or MS/MS
Specimen: peripheral blood
• Targeted and non-targeted metabolomics from
serum samples
• Analysis of several hundred human metabolites by
HPLC-MS or MS/MS
Lipidomics Specimen: peripheral blood
• Targeted analysis of lipids in peripheral blood
• Analysis by LC-MS/MS
Specimen: peripheral blood
• Targeted analysis of lipids in peripheral blood
• Analysis by LC-MS/MS
Proteomics Specimen: peripheral blood
• Targeted analysis of proteome in peripheral blood
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detailed description displaying the data collected in ALLI-
ANCE for children and adults is presented in Table 1.
Questionnaires, structured interviews, telephone interviews
Questionnaires are used to collect information on health
conditions, with an emphasis on respiratory and atopic
symptoms, infections, and sociodemographic and environ-
mental exposures. In children, a baseline questionnaire
further collects information on pre- and perinatal risk fac-
tors including family past medical history. During
follow-up, a further questionnaire assesses the study par-
ticipants’ history during the period prior to the study visit.
Both questionnaires used in the paediatric arm contain
previously validated questions from the International
Study of Asthma and Allergies in Childhood (ISAAC)
[14]. Questionnaires in the adult arm cover the same
topics and adopted the wording of the questions in an
appropriate way. However, while some sections, e.g. pre-
and postnatal risk factors, had to be shortened due to re-
call bias, other questions e.g. on comorbidities and
co-medication were included and further validated ques-
tionnaires are distributed separately (Asthma Control
Test, ACT [15]; Asthma Control Questionnaire, ACQ
[16]; Asthma Quality of Life Questionnaire, AQLQ [17];
Multidimensional Fatigue Inventory, MFI-20 [18]). All
questionnaires are used with little variation since 2012.
For children, all questionnaires are programmed as an
online database for data entry during interview. For
adults, print-out versions of the structured question-
naires are primarily filled in by the patient and
re-checked by the responsible study physician. Add-
itional telephone interviews are used within a time
window of up to one week after scheduled meetings
to collect epidemiological data with use of baseline or
follow-up questionnaires whenever these could not be
completed during study visits.
Objective measurements
For ALLIANCE participants, objective measurements in-
clude routine lung function tests such as spirometry and
bodyplethysmography, but also more specialized tech-
niques such as single and multiple breath washout mea-
surements (SBW and MBW, respectively) [19] to assess
small airway function and ventilation inhomogeneity. This
is complemented by qualitative and quantitative assess-
ments of airway inflammation using exhaled nitric oxide
(eNO) measurements [20] as well as analyses of exhaled
breath with an electronic nose (e-nose, in children only)
[21] and with gas chromatography – mass spectrometry
(GC/MS) [22]. In adults, assessment of small airway func-
tion is additionally performed by impulse oscillometry
(IOS) [23] and capnovolumetry [24]. Objective lung func-
tion measurements in adults are further complemented by
whole body bioimpedance measurement and objectively
measured daily physical activity [25–27]. All measure-
ments are performed according to current guidelines by
Table 2 Completion Rates of Annual Follow-Ups of Cases of the DZL All Age Asthma Cohort (ALLIANCE)
Date: 31/12/2016 Completed Study Visits Documented Drop-Outs Sum Attrition
Pediatric Arm
- Baseline 415 NA NA NA
- 12 months 272 52 324 16.1%
- 24 months 172 17 189 9.0%
- 36 months 16 4 20 20.0%
Adult Arm
- Baseline 208 NA NA NA
- 12 months 153 16 169 9.5%
- 24 months 78 3 81 3.7%
Table 3 Baseline demographics of study participants (cases and
controls) in the DZL All Age Asthma Cohort (ALLIANCE)
Demographic data –
Paediatric Arm, N = 540
Median Interquartile range
Age at baseline study date, yrs 6.6 3.1–11.4
Number Proportion (%)
Sex, male 341 63.1
Current smokera 2 0.9
Demographic data –
Adult Arm, N = 255
Median Interquartile Range
Age at baseline study date, yrs 52.0 43.0–64.0
Number Proportion (%)
Sex, male 117 45.9
Smokerb 60 23.5
Non-smokerb 195 76.5
aIn the pediatric arm only children aged 8 years or more were asked for their
smoking habits (n = 224). Data were missing for n = 12 children
bIn the adult arm current smokers and former smokers with at least 10 pack
years (PY) smoking history were defined as ‘smokers’ (n = 16 (26.7%) and n =
44 (73.3%), respectively); non-smokers could be either never-smokers, or
former smokers with less than 10PY. Among all adult former smokers and
current smokers, mean (range) cumulative tobacco exposure was 9.5 PY (4–20)
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the European Respiratory Society (ERS) and the American
Thoracic Society (ATS) [19, 20, 28–33].
For ALLIANCE study participants and healthy con-
trols, biomaterial collection during study visits include:
peripheral blood samples (inflammatory markers, cell
subpopulations and cytokines, sensitization pattern,
metabolomics, proteomics (in children only), lipidomics,
genomics, transcriptomics, and epigenomics); skin, nasal,
pharyngeal, and nasopharyngeal swabs (microbiome, vir-
ome); collection of nasal secretions (cytokines); primary
epithelial cell scrapings (transcriptome, primary epithe-
lial cell culture); induced sputum samples (cytokines,
microbiome, cell subsets); and urine (metabolomics); as
well as stool samples (microbiome) only in children. Par-
ents of participating children are also asked for a blood
sample (genomics).
Discussion
The ALL Age Asthma Cohort is a large integrative and
interdisciplinary framework containing data on n = 623
patients with wheeze and asthma and n = 172 healthy
controls at baseline. With its comprehensive, standard-
ized molecular approach in a prospective and identical
fashion for children and adults, ALLIANCE aims at (a)
identification of biomarkers and predictors to decode
the complex mechanisms that may underlie the develop-
ment of distinct childhood wheeze and asthma trajector-
ies as well as their transition into and further course
during adulthood, and at (b) translation of this into clin-
ical practice for individual patients.
In addition to the comprehensive and prospective ap-
proach across all ages, ALLIANCE has several methodo-
logical strengths, which are its prime features: the
prospective, observational approach with standardized
data and comprehensive biomaterial collection across all
ages during each study visit in a multi-centre setting to
delineate the different wheeze and asthma phenotypes; the
accurate and standardized measurements of lung function
and markers of airway inflammation, and the stringent
quality control measures involved for every single data
point.
In a broad approach, ALLIANCE aims at decoding the
complex mechanisms that may underlie the development
of distinct childhood wheeze and asthma phenotypes and
their transition into adulthood as well as later adult asthma
phenotypes. As we hypothesize that specific molecular phe-
notypes are associated with distinct wheeze/asthma trajec-
tories, this includes the meticulous longitudinal collection
of routine clinical and epidemiological data and exhaustive
examination of phenotype components that go beyond
medical chart data. Thereby, underlying mechanisms as
well as predictors and biomarkers for such traits can be
identified. For children, this is being applied to study both
participants with established diagnoses and those possibly
on controller therapy, as well as in children which are ster-
oid- and LTRA-naïve, ideally at the earliest possible disease
state.
Thus, we follow a thorough and comprehensive deep
phenotyping approach in cases and healthy controls.
This includes extensive quality control during data col-
lection. In this respect, besides the fact that all measure-
ments are performed according to current guidelines
where available, more than 50 standard operating proce-
dures (SOPs) for data or biomaterial collection as well as
their processing, shipment, and analyses have been de-
veloped. All data collection is being performed in a stan-
dardized way at any age, using the same technique and
equipment on every subsequent occasion in the same
order and according to the numerous harmonized SOPs.
Adherence to these SOPs is ensured by regular field and
lab audits. In addition, structured site visits and team
meetings across all involved centres are performed
regularly.
To explain the association of lung mechanics during
early and late childhood as well as adult age with wheeze
and asthma phenotypes as part of a physiological pheno-
typing, overall lung function, small airway function, and
markers for ventilation inhomogeneity are measured. This
is complemented by qualitative and quantitative assess-
ments of airway inflammation and analyses of exhaled
breath. Lung function tests are performed at several time
points covering important phases of lung development
(further growth of airways and alveoli) during early and
later childhood [34]. Relevant confounders such as phys-
ical activity and auxological as well as developmental fea-
tures are prospectively assessed and will be included in all
analyses. All lung function and eNO measurements are
performed according to the latest ERS/ATS recommenda-
tions, if available [19, 20, 28, 29, 31–33].
There is still limited knowledge on the genetic im-
pact on childhood wheeze and asthma as well as
adult asthma. This is particularly true for cell- or
target-tissue specific up- or downstream events in-
volving epigenetic control as well as gene expression.
Therefore, in addition to genotyping, the assessment
of transcriptomics and epigenomics both in whole
blood, cell-specific (blood cell sub-populations) and
tissue-specific analyses (primary cells of the upper
airways and biosamples from induced sputum) is part
of the deep phenotyping strategy of ALLIANCE.
Another hallmark hypothesis of the consortium is
that individuals at risk for exacerbations can be iden-
tified by clinical and molecular biomarkers, which
might become novel targets for therapy and second-
ary prevention. Therefore, exacerbations will be
assessed by numbers (children and adults) as well as
triggers, severity and clinical features (children only)
via questionnaires at all visits.
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So far, our attrition rates are comparable to other
studies [35, 36]. This may be due to the regular
follow-up in the clinical setting. The drawback of such a
detailed, time-consuming longitudinal study is that it
can only be done on a limited number of participants
due to the significant workload regarding logistics, data
collection and analyses. This extensive biomaterial col-
lection and the number of different analyses and hypoth-
eses is also the reason, why a single power calculation
for the whole cohort is not feasible. Sample size for both
study arms is therefore based on pragmatism and clinical
experience from comparable cohorts.
A significant limitation of ALLIANCE is the inclusion
of cases into the study earliest at the time-point of dis-
ease manifestation, which renders assessment of prior or
even causal determinants acting before disease onset im-
possible. Such assessments can only be performed by
population-based birth cohort studies. Moreover, in con-
trast to cross-sectional comparisons, the lack of pro-
spective follow-up of healthy controls identical to the
setup performed for cases hinders comparability over
time across both strata. Lastly, data on environmental
exposures (e.g. allergen or microbial exposure) are only
collected by questionnaires and not by objective sam-
pling and measurement. Methodology in both study
arms was harmonized as far as possible. However, both
study arms are also used to answer individual research
questions of paediatric and adult pulmonologists, while
other measurements are not feasible or scientifically rea-
sonable. Therefore some objective measurements are
performed in one arm only.
So far, all involved study participants for the paediatric
arm were recruited in participating hospital centres and
private practices of registered paediatricians in the re-
gions of Luebeck, Hannover, Munich, and for the adult
arm in participating hospitals and research centres in
Grosshansdorf and Borstel near Hamburg. Transition
clinics will be established in all three sites to secure con-
tinuous follow-up across the otherwise often neglected
gap between paediatric and adult pneumologist care.
New study centres for the paediatric arm (Marburg,
Cologne) have started recruitment in 2017. While the
main reasons for non-participation especially of
early-onset wheezers is lacking information about the
study as well as the amount of data and biomaterial that
is being collected, all participants are likely to be biased
towards a well-educated middle-class population, which
is the case with numerous studies bringing along de-
tailed data collection. Moreover, this is an observational
study within a clinical setting with desirable results to be
applied in such environments. Hence, results will be less
applicable for the general population than for individuals
presenting to seek medical care in the case of wheeze
and asthma.
In this clinical context, ALLIANCE offers improved
endo-phenotyping in children and adults identically to
delineate different underlying pathophysiological path-
ways across asthma phenotypes in a longitudinal way.
With its standardised and unique dataset of detailed epi-
demiological, physiological, and deep phenotyping of a
comprehensive range of biomaterials across all ages in a
considerable number of study participants, it will enable
to decode mechanisms underlying the asthma syndrome,
as well as their translation to well-defined patient groups
and possibly even the individual patient.
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